
|Articles|June 1, 2001
Studies confirm low-dose oral contraceptive treats acne effectively
Washington - The results of Phase III clinical trials demonstrate the safety and efficacy of a low-dose oral contraceptive containing ethinyl estradiol 20 mcg and levonorgestrel 100 mcg (Alesse) for the treatment of moderate acne, reported Diane M. Thiboutot, M.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











